COGSCREEN II Early Identification of Cognitive Problems in Adults 60 and Older Using Screening by General Practitioners and Specialists in Germany

What this Trial Is About

Researchers are investigating the early detection of cognitive decline in older adults to better identify Alzheimers disease AD at its earliest stages. The study focuses on individuals aged 60 and above who may show subjective cognitive deficits or mild cognitive impairment, which can indicate early AD. Early identification is important for dementia prevention and to prepare for future disease-modifying treatments. This project builds on a network of general practitioners and specialists to improve detection outside specialist clinics, addressing current low diagnostic rates. Participants will be involved in a randomized study comparing two groups one receiving blood-based biomarker testing alongside digital cognitive assessments, and one without blood biomarker testing. The study introduces proprietary digital cognitive tests and blood biomarker tools to participating physicians. This approach aims to create a precision medicine model for early AD diagnosis, focusing on community-based healthcare settings. The study will last for about two years on average. During the study, researchers will monitor the percentage of participants diagnosed with Alzheimers disease supported by blood biomarker evidence. They will also assess diagnostic costs, clinical management changes, and acceptance of screening tools by both physicians and participants. Various questionnaires, cognitive tests, and biomarker analyses will be used to evaluate the effectiveness and user experience of the screening methods throughout the study duration.

COGSCREEN II: Early Detection of Cognitive Impairment